A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > BUSINESS
BUSINESS
- Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
- Upcoming Reforms “Ideal” for Promoting Use of Generic Drugs: President Sawai of Sawai Pharm.
March 13, 2012
- Nippon Shinyaku and Taiho to Cancel Licensing Agreement for Novel Antipruritic Agent
March 12, 2012
- UMN, IHI Start Construction of Biopharmaceutical Manufacturing Plant
March 12, 2012
- Novartis to Transfer Zaditen Ophthalmic Solution Marketing Rights to Alcon Japan
March 12, 2012
- Sosei Initiates PI Trial for Oropharyngeal Candidiasis Treatment SO-1105
March 12, 2012
- Taiyo to Discontinue Marketing Around 50 Products; Started Notifying Customers Last May
March 12, 2012
- Novo Nordisk Applies for Fixed-Dose Insulin Treatment
March 12, 2012
- Most Admired Pharma Companies in Japan
March 12, 2012
- Asahi Kasei to Acquire ZOLL Medical of the US for US$2.21 Bil.
March 12, 2012
- Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic While Patent Dispute Continues
March 12, 2012
- 5th Annual Marketing Excellence Japan 2012 – Hilton Tokyo, May 15 - 16
March 9, 2012
- 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
- Novartis Voluntarily Recalls 720,000 Diovan Tablets due to Insect Contamination
March 9, 2012
- The Earthquake-Hit Regions Today 3: “Inventory”as an Edge, Changes in Risk Management
March 9, 2012
- Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
- Daiichi Sankyo Says Mr Yoshiwaka to Become Espha President
March 8, 2012
- MTPC Enters into Agreement for Joint Research of New Vaccines with Canadian Company
March 8, 2012
- US FDA Does Not Approve Additional Indication of AML for Eisai’s Dacogen
March 8, 2012
- “Absolutely No Intention” of Moving Headquarters from Osaka: President Teshirogi of Shionogi
March 8, 2012
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…